SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently facing intense selling pressure, with community sentiment shifting between aggressive short-selling and debate over whether current price levels represent a structural breakdown or a buying opportunity. Discussions are dominated by concerns over crowded positioning, potential contract renewals, and skepticism regarding valuation, as participants closely monitor key support levels to determine if the stock is nearing a bottom.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion Inc. is trending following the White House's announcement of new executive orders focused on quantum sensing and networking, which positions the company as a key beneficiary in the quantum sector. Investors are actively discussing the stock's long-term potential, its upcoming Russell 3000 inclusion, and the impact of government-backed quantum initiatives on the broader technology landscape.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors debate the impact of leadership changes, including the upcoming departure of the CFO, while closely monitoring progress in the company's oncology pipeline following recent trial updates. Market participants are actively discussing the stock's long-term valuation and the effectiveness of current growth strategies in the competitive biotech landscape.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is drawing significant investor interest as shareholders bet on a long-term turnaround fueled by international expansion, a new CEO, and persistent buyout speculation involving major stakeholders. The community remains heavily focused on the stock's elevated short interest, with many retail traders actively discussing the potential for a short squeeze despite ongoing concerns regarding operational efficiency and food quality.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics (DFTX) is experiencing heightened investor interest driven by positive Phase 3 data for its MDD therapeutic and anticipation of a series of upcoming pivotal trial milestones. The community is actively debating the company's long-term commercialization prospects and the impact of a recent major public offering, with many investors weighing the potential for a breakthrough against the risks of dilution and the competitive landscape for psychedelic-based medicine.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as investors react to the company's roadmap for gate-model quantum simulators and potential expansion into government-backed quantum initiatives. The community remains highly polarized, with intense debate between long-term bulls betting on quantum supremacy and skeptics focused on high cash burn, heavy insider selling, and extreme valuation concerns.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is seeing intense investor attention and increased trade volume following a significant purchase order for its NeuraWave photonic reservoir systems and broader sector momentum surrounding government-led quantum technology initiatives. The community remains highly focused on the company's hardware commercialization progress and the potential for a short squeeze, given the substantial short interest and heavy call option activity.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is drawing intense community focus as domestic policy shifts spotlight its role in national quantum computing and defense supply chains, fueling a debate between those betting on its long-term industrial moat and others questioning the pace of its legacy software transition. Traders are closely monitoring the stock's support levels while speculating on further government-backed equity or contract opportunities tied to its AI and quantum infrastructure.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is facing intense downward pressure as retail investors grapple with post-IPO volatility and concerns over its massive valuation relative to current revenue. The community is sharply divided, with many debating whether the stock is a long-term play on AI and space infrastructure or a temporary hype-driven rug pull that will see further declines before finding a floor.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is attracting significant retail and institutional interest as investors track substantial share accumulation by CEO Kevin Tang and speculate on a potential buyout. While the company maintains clinical progress and steady commercial performance, the community remains divided, weighing the upside of recent insider activity against long-standing frustration over management transparency and sluggish price movement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential first-in-class integrin beta-6 (IB6) directed antibody-drug conjugate (ADC). The study enrolled adults with...

AI, Biotech, And Healthcare Catalysts Drive Momentum

Several emerging public companies are attracting attention as artificial intelligence, healthcare innovation, medical technology, and international commercialization strategies continue converging across the market. From AI-powered drug discovery and regenerative medicine expansion to precision dermatology and medical device innovation, recent developments highlight how smaller companies are positioning themselves around some of the fastest-growing sectors in healthcare and technology. $TGNT, $NXTS, $AZTR, $ADTX, $TNON, $PFE

Pfizer Stock Edges Lower Monday: What's Going On?

Pfizer shares are trading lower by about half a percent on Monday as investors digest a leadership transition in the finance seat.read more...

Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?

SNY's Dupixent is expanding into new diseases and geographies, strengthening its position as a key driver of long-term revenue growth.

Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?

Amvuttra is the primary driver of ALNY's revenues, but growth from Givlaari, Oxlumo and Leqvio may help diversify the company's top line.

Pfizer Isn't Expecting to Make Any Big Acquisition in the Next Couple of Years, but It's Planning to Do This Instead

Key PointsPfizer has leaned on acquisitions in recent years to strengthen its growth prospects...

Could Pfizer Stock Be Your Ticket to Generational Wealth?

Key PointsPfizer is one of the world's most respected pharmaceutical companies...

Own 500 Shares of Pfizer and JNJ and Here's Your Annual Dividend Income

Own 500 Shares of Pfizer and JNJ and Here's Your Annual Dividend Income...

Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?

Key PointsEli Lilly is a market darling because it is a leader in the GLP-1 weight-loss market...

PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed

Pfizer shares fall after CFO Dave Denton announces his exit, though the company reaffirms 2026 guidance and maintains its strategic outlook.

This account has been verified as an official PFE representative.

Verified Account

PFE Stock Drops 3% On Surprise CFO Exit Despite Reaffirmed 2026 Guidance

Equity

Bullish Sentiment

Track PFE stock price, charts, news and real-time market activity on Stocktwits. Join the PFE message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Pfizer Inc stock.

PFE Stock Price Today - Pfizer Inc News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Investor frustration is mounting after the company's Phase 3 lung cancer trial failed to meet its primary overall survival endpoint.

Traders are actively debating the company's role as a potential acquirer in the ongoing oncology merger and acquisition frenzy.

Shareholders are fiercely divided over whether current low prices and high dividend yields represent a solid buying opportunity or a deeper issue.

Feed

News

Sentiment

Earnings

Fundamentals

Info

PFEPfizer Inc

Fundamentals

Latest PFE News